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Synopsis 
Background 
Long-term care facilities (LTCFs) are thought to be important reservoirs of antimicrobial-resistant 
(AMR) bacteria; however, there is no routine surveillance of resistance in LTCF residents, or large 
population-based studies comparing AMR in LTCFs with the community, so the relative burden of 
AMR in LTCFs remains unknown.  
Objectives 
To compare the frequency of antibiotic resistance of urinary tract bacteria from residents of LTCFs 
for the elderly and adults aged over 70 or older living in the community.  
Methods 
Positive urine specimens reported to any diagnostic microbiology laboratory in the West Midlands 
region (England) from 01/04/2010 to 31/03/2014 collected from individuals over 70 years old were 
analysed. The resistance of Escherichia coli and Klebsiella to trimethoprim, nitrofurantoin, third-
generation cephalosporins (3GCs), and ciprofloxacin and the rate of laboratory confirmed E. coli and 
Klebsiella urinary tract infection (UTI) were assessed in LTCF residents and in the community.  
Results 
LTCF residents had a laboratory confirmed E. coli and Klebsiella UTI rate of 21 per 100 person years 
compared to eight per 100 person years in the elderly living in the community (rate ratio (RR)=2.66, 
95% CI=2.58-2.73) and a higher rate of developing E. coli and Klebsiella UTIs caused by bacteria 
resistant to trimethoprim (RR=4.41, 95% CI=4.25-4.57), nitrofurantoin (RR=4.38, 95% CI=3.98-4.83), 
ciprofloxacin (RR=5.18, 95% CI=4.82-5.57), and 3GCs (RR=4.49, 95% CI=4.08-4.94).  
Conclusions 
Residents of LTCFs for the elderly had more than double the rate of E. coli and Klebsiella UTI and 
more than four times the rate of E. coli and Klebsiella UTI caused by antibiotic-resistant bacteria 
compared to those living in the community. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The spread of antimicrobial resistance (AMR) is a major healthcare concern.1 Due to the paucity of 
new antibiotics being developed, a rise in AMR limits treatment options and increases the risk of 
treatment failure, leading to increases in morbidity and mortality.2 Of particular concern are recent 
increases in hospital infections due to strains of Gram-negative bacteria such as Klebsiella and 
Escherichia coli that are resistant to all first-line antibiotics.1,3 Gram-negative bacteria are now the 
most common cause of hospital-acquired infection in England, Wales, and Northern Ireland, causing 
50,000 (63%) blood stream infections (BSI) in adults in 2011/12.1 They were also the most common 
cause of BSI in Scotland in 20124. E. coli and Klebsiella are organisms of particular concern and have 
been highlighted as bacteria to monitor for resistance in the 5 year AMR strategy for the UK (2013-
2018).5 E. coli BSIs in England have increased by 15.6% from 2010 to 2014 and Klebsiella pneumoniae 
BSIs in England have increased by 20.8% from 2009 to 2014. BSIs caused by other species have 
remained constant or declined.6  
Elderly individuals, particularly long-term care facility (LTCF) residents, are at increased risk of 
infection-related hospital admissions.7 Infections and colonisation in patients ≥65 years old are more 
likely to be caused by AMR bacteria, although this varies for different pathogen-antibiotic 
combinations.8–11 Urinary tract infections (UTIs), caused primarily by Gram-negative bacteria such as 
E. coli, Proteus and Klebsiella, are the second most frequent type of infection for elderly women.12,13 
In England, UTIs were found to be the second most common healthcare-associated infection after 
respiratory tract infections, both in the hospital setting (17.2%) and the LTCF setting (35.7%).14,15 
UTIs were the joint most common healthcare-associated infection with respiratory tract infections 
(31%), in a point-prevalence survey carried out in LTCFs across Europe.15  
It is estimated that in England, 4% of those aged over 65 (325,000 people) live in LTCFs.7 Like 
hospitals, LTCFs are enclosed environments with high concentrations of frail elderly residents who 
are more likely to require daily living assistance, antibiotic treatment, and invasive devices such as 
catheters.16 At any one time in Europe between 4.8% and 15.2% of LTCF residents are being treated 
with antibiotics and between 47% and 79% of LTCF residents in Canada, USA, and Italy receive at 
least one course of antibiotics per year.17 In Hampshire (England), residence in a LTCF has recently 
shown to be associated with high antibiotic consumption.18 Control of infections can be challenging 
in LTCFs due to frequent opportunities for transmission through group activities, sharing of living 
space, objects and bathroom facilities, and lack of infection control provision.16  
AMR is not routinely surveyed in LTCFs, such that the extent of the problem is hidden and there is a 
lack of coordinated action to address the issue. We aimed to compare the frequency of antibiotic 
resistance of urinary tract bacteria from residents of LTCFs for the elderly and adults aged over 70 
living in the community. To our knowledge, there are no large population-based studies which 
include samples from both GPs and hospitals that have addressed this question.  
 
 
 
 
 
 
 
 
 
 
Methods 
Ethics 
PHE has National Information Governance Board for Health and Social Care (NIGB) approval for the 
collation and analysis of this surveillance data in accordance with section 251 of the NHS Act 2006. 
This study was a secondary analysis of routinely collected AmSurv data.  
Data sources 
Three sources of data were used in this study. Firstly, the antibiotic susceptibility results from all E. 
coli or Klebsiella culture positive urine specimens collected from individuals over 70 years of age 
reported from the 15 microbiology laboratories in the West Midlands to AmSurv (an AMR 
surveillance tool19) from 01/04/2010 to 31/03/2014. The West Midlands Region (England) comprises 
a population of 700,000 over the age of 70.20 Following national guidelines, we assumed that all 
urine samples were submitted due to clinical need and, therefore, were indicative of a suspected 
UTI.21 The dataset did not contain sufficient clinical information to identify urine samples from 
catheters or distinguish between UTIs and asymptomatic bacteriuria, common in the elderly 
population in particular amongst those residing in LTCFs.22 Samples from all types of suspected UTIs 
were considered. All West Midland laboratories undertake UKAS external accreditation to verify 
competencies and assure of conformity to standard methods.23 Laboratory information systems are 
configured to only send significant bacteriuria to PHE and PHE recommends specific cut-offs for 
clinical laboratory processing.24 Resistant bacteria were either fully resistant or intermediately 
resistant to a particular antibiotic. Clinical laboratories in England perform antibiotic susceptibility 
testing using a variety of methods: EUCAST (The European Committee on Antimicrobial Susceptibility 
Testing), BSAC (The British Society for Antimicrobial Chemotherapy) and CLSI (Clinical Laboratory and 
Standards Institute); with a mix of automated (eg VITEK, Phoenix) and manual laboratory methods 
(eg disc and E-test). All laboratories who contribute to this dataset participate in the UK National 
External Quality Assurance Scheme (NEQAS). Clinical laboratories most commonly use EUCAST 
breakpoints, and until recently BSAC methodology, but where EUCAST breakpoints are unavailable 
for key antibiotics, laboratories use alternative published breakpoints such as NCCLS, and are asked 
to report their methods to NEQAS when reporting specific organism antibiotic susceptibility results. 
Specifically in the West Midlands, in 2012, out of 15 laboratories, seven laboratories used BSAC disc 
diffusion, four used Vitek 2, three used breakpoint methods and one used a combination of Vitek 2 
and BSAC disc diffusion (depending on if tests were performed during normal working hours) to test 
antibiotic susceptibility 25. The breakpoint method involves seeding agar plates with a concentration 
of antibiotic equivalent to the breakpoint for each antibiotic26. Diluted organisms are spotted on the 
antibiotic plates and on control plates containing no antibiotics. Seven of the eight laboratories using 
the BSAC method reported using the latest breakpoints during the study period. The remaining 
laboratory used an earlier version (version 10). Vitek 2 software uses EUCAST v1.1 (2010) 
breakpoints. During the study, two laboratories switched from using the BSAC method to a 
breakpoint technique.  
The CLSI breakpoints for ceftazidime (one of the four 3GC tested) changed in 2010 and this change 
was implemented in automated systems between 2012 and 2013. In 2012, no laboratories in the 
West Midlands reported using CLSI breakpoints for this antibiotic. However, the methods used may 
have changed from 2012 to 2014, which is a limitation of the percentage of 3GC reported. However, 
in our dataset, ceftazidime resistance constituted a fraction of what we report as third-generation 
cephalosporin resistance (33% of 3GCs tests for Klebsiella and 19% for E. coli) and there was no 
stepwise increase nor decrease in the %urinary E. coli and Klebsiella resistant to cefazidime in any of 
the West Midlands laboratories. In addition, across all non-specialist microbiology laboratories in the 
region, 50% of urine samples come from the community with LTCFs sending samples to their closest 
laboratory rather than having a specific managed contract with one laboratory within the region. 
Data cleaning and de-duplication is described in Appendix 1a and Figure S1.  
LTCF status (nursing or residential), bed numbers for the entire LTCF, and LTCF postcodes were 
extracted from the publicly available registry of LTCFs by the national regulator of health and social 
care in England (the Care Quality Commission).27 LTCFs in the national register were included if they 
were classified as “care homes” for elderly residents and recorded as active in the register from 
2011/2012 (797 LTCFs). Care homes, as defined by the Care Quality Commission, “offer 
accommodation and personal care for people who may not be able to live independently”.28 We 
subsequently refer to care homes with 24-hour medical care from qualified nursing staff as nursing 
LTCFs and to care homes without this service as residential LTCFs.  
Postcodes containing only communal establishments (CE-pc) in the West Midlands and age stratified 
population estimates for mid-2014 were taken from open data held by the Office for National 
Statistics (ONS).20,29  
Data linkage 
LTCF residence was determined by matching individuals’ full postcodes, based on the request form 
for microbiological investigation, against the full postcodes of LTCFs in the West Midlands region 
registered with the Care Quality Commission as of April 2014. In this manuscript, samples from 
individuals residing in a postcode that contained a LTCF (LTCF-pc) are referred to as LTCF samples 
and those with a postcode that did not (non-LTCF-pc) are referred to as non-LTCF samples.  
Crude rate comparisons 
Positive urinary tract bacterial cultures with E. coli and Klebsiella reported to AmSurv were used as a 
surrogate for E. coli and Klebsiella UTI, as urinary tract specimens should only be sent to the 
microbiology laboratory when there is a clinical suspicion of a UTI21. E. coli and Klebsiella samples 
were grouped as these were the most common Gram-negative bacteria with similar antibiotic 
treatment. Proteus isolates were not included as these bacteria are to be intrinsically resistant to 
nitrofurantoin.30 The rates of E. coli and Klebsiella UTI and E. coli and Klebsiella UTI caused by 
resistant bacteria in LTCF-pc and in non-LTCF-pc are calculated as per Appendix 1b.  
Postcodes may cover several buildings; therefore, LTCF postcodes may also include some elderly 
people who are not LTCF residents. Sensitivity analysis estimated the rates of E. coli and Klebsiella 
UTI in LTCFs using only data from LTCF postcodes that were classified by the ONS as “communal 
establishment only” postcodes (LTCF CE-pc).  
Comparison of resistance levels in culture confirmed samples 
Logistic regression models coded in the rms package in R were used to calculate the odds of 
resistance for bacteria in LTCF samples compared to non-LTCF samples.31 Further analyses compared 
nursing and residential LTCFs. Age group (70-74 , 75-80, 81-85, and >85), sex, year of study 
(2010/2011, 2011/2012, 2012/2013, and 2013/2014), and sender (GP versus hospital) were included 
in the model as categorical covariates because they are known risk factors of antibiotic resistance for 
urinary tract bacteria (see Appendix 1c). No interactions between the model variables improved 
model fit, therefore, they were not included in the final model (see Table S1). 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
144,738 individuals over 70 years old had at least one positive urine specimen reported to the 
AmSurv database from any of the 15 diagnostic microbiology laboratories in the West Midlands 
region. The most commonly reported bacterium in the dataset was E. coli (57.2%). Klebsiella spp. 
accounted for 6.2% of the samples (of which 65% were K. pneumoniae, 19% K. oxytoca, and 15% 
other Klebsiella of undefined species).   
Table 1 describes the key characteristics of E. coli and Klebsiella in LTCF samples and non-LTCF 
samples. LTCF samples were more frequently reported from very elderly age groups (>85) than non-
LTCF samples. LTCF samples (and non-LTCF samples) comprised samples both sent by GPs and 
hospitals (eg. during a LTCF resident’s hospital stay). LTCF samples were more frequently sent by GPs 
(versus hospitals) than non-LTCF samples. Overall, most samples were taken from females. This 
difference in gender was greater for LTCF samples than for non-LTCF samples.  
The rate of laboratory confirmed E. coli and Klebsiella UTI was 20.6 per 100 person years in LTCF 
residents and 7.8 per 100 person years in community dwelling older adults; giving a rate ratio (RR) of 
2.66 (95% CI=2.58-2.73) (see Table 2).  In the sensitivity analysis, the rate of E. coli and Klebsiella UTI 
in the LTCFs located in CE-pc was similar (21.5 per 100 person years) giving a similar RR of 2.77 (95% 
CI=2.57-2.98) (see Table S2). 
The rate of E. coli and Klebsiella UTI caused by bacteria resistant to trimethoprim per 100 person 
years was 12.7 in LTCF residents versus 2.9 in community residents (RR=4.41, 95% CI=4.25-4.57) (see 
Table 2). The rate of E. coli and Klebsiella UTI caused by bacteria resistant to nitrofurantoin per 100 
person years was 1.7 in LTCF residents versus 0.4 in community residents (RR=4.38, 95% CI=3.98-
4.83). The rate of E. coli and Klebsiella UTI caused by bacteria resistant to ciprofloxacin per 100 
person years in LTCF residents was 3.3 versus 0.6 in community residents (RR=5.18, 95% CI=4.82-
5.57). The rate of E. coli and Klebsiella UTI caused by bacteria resistant to third-generation 
cephalosporins (3GC) per 100 person years in LTCF residents was 1.8 versus 0.4 in community 
residents (RR=4.49, 95% CI=4.08-4.94). The sensitivity analysis yielded very similar findings, with 
LTCF residents having a higher rate of E. coli and Klebsiella UTI caused by bacteria that were resistant 
to trimethoprim (RR=4.44, 95% CI=4.04-4.89), nitrofurantoin (RR=4.82, 95% CI=3.77-6.16), 
ciprofloxacin (RR=7.88, 95% CI=6.76-9.19), and 3GCs (RR=4.09, 95% CI=3.14-5.33) (see Table S2). 
The prevalence of antibiotic resistance was higher in bacteria from LTCF samples than in non-LTCF 
samples for all bacterium-antibiotic combinations (Tables 3 and 4). E. coli resistance to trimethoprim 
was 60% versus 37% (adjusted odds ratios (aORs)=2.36, 95% CI=2.21-2.53); nitrofurantoin 7% versus 
4%  (aOR=1.74, 95% CI=1.53-1.97); ciprofloxacin 29% versus 14% (aOR=2.42, 95% CI=2.17-2.69); and 
3GCs 10% versus 6% (aOR=1.89, 95% CI=1.64-2.17). Klebsiella resistance to: trimethoprim was 41% 
versus 26% (aOR=1.89, 95% CI=1.6-2.24); nitrofurantoin 41% versus 34% (aOR=1.31, 95% CI=1.09-
1.59); ciprofloxacin 10% versus 8% (aOR=1.54, 95% CI=1.13-2.1); and 3GCs 8% versus 7% (aOR=1.24, 
95% CI=0.85-1.83). Further results of the univariate and multivariate results are shown in Tables S3-
S9 and Appendix 1d. 
LTCFs with nursing support had higher levels of resistance to most antibiotics than residential LTCFs 
(see Table 3 and Table S10). Levels of antibiotic resistance were also higher in urinary tract bacteria 
from LTCF residents (obtained both from GPs and hospitals) than from hospitals (including samples 
from residents of LTCF-pc and non-LTCF-pc) (Table S11). E. coli resistance to trimethoprim, 
nitrofurantoin, ciprofloxacin and 3GCs was higher in LTCF samples than in hospital samples (60% 
versus 40%, 7% versus 4%, 29% versus 16%, and 11% versus 8%). Klebsiella resistance to 
trimethoprim and nitrofurantoin was also higher in LTCFs (41% versus 27% and 41% versus 32) but 
ciprofloxacin resistance was similar (10% versus 10%) and 3GCs resistance was higher in hospitals 
(8% versus 10%).  
There were differences in resistance to trimethoprim, nitrofurantoin, ciprofloxacin, and 3GCs over 
the study period for bacteria from LTCF samples and non-LTCF samples. These patterns are plotted 
in Figure 1. Resistance to other antibiotics are plotted in Figures S2 and S3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
Elderly residents of LTCFs are more than twice as likely as community dwelling adults of similar age 
to present with a laboratory confirmed E. coli or Klebsiella UTI. These infections are most commonly 
caused by E. coli. In LTCF residents 60% of samples that yielded E. coli were resistant to 
trimethoprim, 29% to ciprofloxacin, 10% to 3GC, and 7% to nitrofurantoin; 41% of samples that grew 
Klebsiella were resistant to trimethoprim, 41% to nitrofurantoin, 10% to ciprofloxacin, and 8% to 
3GCs. LTCF residents were more than four times more likely than community dwelling older people 
to develop a laboratory confirmed E. coli or Klebsiella UTI caused by resistant bacteria. The increased 
risk of antibiotic resistance amongst bacteria causing culture confirmed E. coli and Klebsiella UTIs in 
the elderly residing in LTCFs is seen across antibiotic classes.  
Since 2012, all laboratories in the West Midlands report to AmSurv, making data from this region the 
most complete source of AMR data and providing insight into the burden and temporal changes of 
AMR within a defined population. Matching patient postcodes to LTCF postcodes registered by the 
national regulator of health and social care in England unearths unprecedented knowledge of AMR 
in this setting over four years. The AmSurv surveillance system collects routine diagnostic samples 
from both community and hospital settings, permitting a fuller understanding of AMR in the 
population than other surveillance systems. In the multivariable analyses, statistically significant 
differences between the odds of antibiotic resistance in LTCF and non-LTCF settings are adjusted for 
clustering at the postcode level and account for variation in antibiotic resistance due to key risk 
factors (e.g. samples being sent from hospitals). Differences between residential and nursing LTCFs 
were also explored.  
There were a number of limitations associated with using a large surveillance dataset. The dataset 
did not contain sufficient clinical information to identify urine samples from catheters or distinguish 
between UTIs and asymptomatic bacteriuria, common in the elderly population in particular 
amongst those residing in LTCFs.22 However, clinical guidelines emphasise that only urinary samples 
from patients with a clinically suspected UTI, and either a risk factor for resistance or a history of 
UTIs should be sent for laboratory testing, and that catheter samples should not be sent.21,32 This 
dataset only included positive samples. The likelihood of an elderly individual with a UTI having a 
urinary sample submitted might differ in LTCF residents and those living in the community, which 
could bias results. Separately, there is evidence for variation in the rate of submission of community 
samples from GPs to laboratories.33 This is an unquantified potential confounder; however, this 
variation should be less pronounced in older populations, as English national guidance advocates 
sampling all patients over 65 years old with two or more signs of UTI.34 Sampling may be biased 
towards those failing to respond to treatment, which could increase the apparent risk of resistance. 
However, it is unclear why this bias would be greater in LTCF samples than in samples from the 
community. Urinary tract samples reported to AmSurv with confirmed culture results for E. coli and 
Klebsiella accounted for 63% of urinary tract bacteria samples. Caution must therefore be applied 
before extrapolating our results to UTIs caused by other bacterial species. Another limitation is that 
the threshold to diagnose UTI might be lower in LTCFs as staff might notice UTI symptoms earlier 
than would otherwise be detected in individuals living in their own homes. Also, cognitive 
impairment was not recorded. Therefore, the analysis could not take into account differences in this 
condition in the two populations, which may lower the diagnosis threshold due to the inability of 
patients to verbalise symptoms. The study also is limited by the in vitro measurement of resistance, 
which does not always equate to clinical failure. It should also be noted that different breakpoints 
for ceftazidime (one of the four 3GC tested) may have been used during the time period. However, 
the majority of laboratories were using BSAC/EUCAST breakpoint standards and this change was not 
apparent in our data (see methods section for details). Finally, since LTCF residence is not routinely 
recorded, we needed to infer this from patient postcodes. Thus, whilst those living in non-LTCF 
postcodes are highly unlikely to be LTCF residents, a proportion of those living in LTCF postcodes will 
live in the community in neighbouring households.  This will tend to bias odds ratios toward the null 
hypothesis, potentially leading to underestimates of the impact of LTCF residence on antibiotic 
resistance. LTCF UTI rates were similar when using the more specific postcodes that contained only 
communal establishments, suggesting that this bias was minimal. This methodology has previously 
been employed in other studies.7,18 
Trimethoprim and nitrofurantoin are recommended as first-line treatments for UTI,35 therefore, 
resistance to these agents can result in treatment failure, hospitalisation, and the subsequent use of 
antibiotics such as ciprofloxacin or 3GCs that should be reserved for the treatment of more serious 
infections. Our findings suggest that a large proportion of E. coli and Klebsiella UTIs in the elderly will 
not respond to trimethoprim treatment and that this problem is heightened in LTCFs, where the 
prevalence of resistance is even higher. 39% of UTIs caused by E. coli and 27% of UTIs caused by 
Klebsiella (60% and 41%, respectively, in LTCFs) were resistant to trimethoprim, which is the most 
commonly prescribed antibiotic of those recommended in empiric guidelines for lower UTI (54.2%).36 
One explanation for these high levels of resistance could be the high consumption of this antibiotic 
in England (6.4% of all antibiotics consumed in the community and 3.9% in hospitals in 2013).36 
Resistance to trimethoprim increased during the study period, faster for LTCF samples (E. coli from 
53% to 63% and Klebsiella from 34% to 43%) than for non-LTCF samples (E. coli from 35% to 38% and 
Klebsiella from 22% to 29%). These increases could partly be explained by trimethoprim 
consumption increasing in England by 4.2% between 2010 and 2013.36 The prevalence of resistance 
of E. coli and Klebsiella against nitrofurantoin was high for Klebsiella (35%) but much lower for E. coli 
(4%). This suggests nitrofurantoin might still remain very effective in treating UTIs caused by E. coli in 
the elderly, particularly in women, where the aOR of acquiring a UTI caused by nitrofurantoin 
resistant E. coli are lower. Nitrofurantoin comprised 3.8% of all antibiotics consumed in England in 
2013 in the community and was the second most frequently prescribed antibiotic agent of those 
recommended in empiric guidelines for lower UTI (20.8%).36 In the West Midlands, the consumption 
of nitrofurantoin increased by 66% from 2010 to 2014.6 
Ciprofloxacin, 3GCs, and carbapenems are antibiotics that are almost exclusively administered in 
hospitals for the treatment of severe infections. Ciprofloxacin treatment is recommended only in 
UTIs with acute prostatitis or acute pyelonephritis and 3GCs are not recommended in the empiric 
treatment of UTIs but are needed to treat more severe infections such as bacterial meningitis.35,36 
Given this, the prevalence of resistance to ciprofloxacin in E. coli (15%) is concerning, in particular in 
LTCF samples (29%). The levels of resistance to ciprofloxacin in Klebsiella and to 3GC in E. coli and 
Klebsiella were lower (8%, 6%, and 7%, respectively). Although low, Klebsiella resistance to 
ciprofloxacin and 3GC increased steadily during the study period for LTCF samples (from 6% to 14% 
for ciprofloxacin and 3% to 12% for 3GCs) and also increased, although slower, in non-LTCF samples 
(7% to 10% for ciprofloxacin and from 6% to 9% for 3GCs). E. coli resistance to ciprofloxacin and 
3GCs remained stable. During the study period, quinolone consumption in the West Midlands 
remained fairly stable but the consumption of 3GCs increased by 21%.6 Importantly, 3GC and 
ciprofloxacin resistances do not only result in treatment failures but in the prescription of “last 
resort” antibiotics such as carbapenems.1 In our study, the prevalence of resistance in urinary tract 
bacteria to carbapenems in the over 70s was similarly low in both Klebsiella and E. coli (0.2% and 
0.02%, respectively) to what has been reported in the literature between 2010 and 2013 in the 
overall West Midlands population;25 which prevented any formal statistical analysis but is reassuring. 
This is the first large population study to formally compare AMR in LTCF residents to that in the 
elderly living in the community combining hospital and GP surveillance data. It is also the first large 
scale study to quantify the burden of AMR in English LTCFs, where resistance levels and the LTCFs 
themselves could be different to LTCFs in other countries. Other studies were too small to yield 
statistically robust conclusions for several resistances, did not include GP samples or did not carry 
out a formal statistical comparison. 37–42 Our findings highlight the very high levels of AMR bacteria in 
LTCF residents compared to their community counterparts and even to hospital patients; showing 
the importance of reducing antibiotic usage in LTCFs through antibiotic stewardship programmes 
and the need for LTCF specific surveillance that can guide empiric treatment. We found that that a 
very high proportion of E. coli and Klebsiella UTIs in the elderly living in LTCFs (and a high proportion 
of those living in their own homes) will not respond to trimethoprim treatment. However, resistance 
to nitrofurantoin remains low in UTIs caused by E. coli but high in UTIs caused by Klebsiella, 
demonstrating the need to further understand the mechanisms for the selection of resistance. In 
order to understand why there are such high levels of resistance in LTCFs, more information about 
antibiotic prescription, recent hospitalisations, and transmission of resistant bacteria is required. It is 
equally important that interventions are developed to reduce the risk of transmission of AMR 
bacteria in LTCF residents. 
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Tables 
Table 1. Characteristics of urine E. coli and Klebsiella positive samples.  
  LTCF E. coli 
samples 
(N=17,022) N(%) 
Non-LTCF E. coli 
samples 
(N=154,453) N(%) 
LTCF Klebsiella 
samples 
(N=1,510) N(%) 
Non-LTCF 
Klebsiella samples 
(N=21,262) N(%) 
Age 
Age 70-74 807 (4.7%) 34,984 (22.7%) 91 (6.0%) 4,621 (21.7%) 
Age 75-80  2,038 (12.0%) 45,300 (29.3%) 222 (14.7%) 6,445 (30.3%) 
Age 81-85 3,573 (21.0%) 35,178 (22.8%) 308 (20.4%) 5,034 (23.7%) 
Age >85 10,604 (62.3%) 38,991 (25.2%) 889 (58.9%) 5,162 (24.3%) 
Gender 
Female 14,406 (85.0%) 124,547 (80.7%) 1,080 (71.8%) 13,150 (61.9%) 
Male  2,545 (15.0%) 29,753 (19.3%) 425 (28.2%) 8,094 (38.1%) 
LTCF type 
Residential  10,139 (59.6%) N/A 823 (54.5%) N/A 
Nursing  6,883 (40.4%) N/A 687 (45.5%) N/A 
Year of study 
Year 1  2,541 (14.9%) 25,220 (16.3%) 247 (16.4%) 3,615 (17.0%) 
Year 2  3,958 (23.3%) 33,396 (21.6%) 337 (22.3%) 4,926 (23.2%) 
Year 3  4,911 (28.8%) 43,784 (28.4%) 414 (27.4%) 6,007 (28.3%) 
Year 4  5,612 (33.0%) 52,053 (33.7%) 512 (33.9%) 6,714 (31.6%) 
Sender 
GP  12,571 (74.1%) 99,727 (64.9%) 1,033 (68.5%) 11,369 (53.5%) 
Hospital  4,396 (25.9%) 54,011 (35.1%) 475 (31.5%) 9,872 (46.5%) 
 
 
 
Table 2. Rate of E. coli and Klebsiella UTI and E. coli and Klebsiella UTI caused by antibiotic-resistant bacteria for LTCF 
and non-LTCF residents* per 100 person years. 
  
LTCF rate non-LTCF rate 
rate 
ratio 
95% CI 
UTI^ 20.6 7.8 2.7 2.6-2.7 
UTI^ caused by bacteria resistant to trimethoprim 12.7 2.9 4.4 4.3-4.6 
UTI^ r caused by bacteria resistant to nitrofurantoin 1.7 0.4 4.4 4.0-4.8 
UTI^ caused by bacteria resistant to ciprofloxacin^ 3.3 0.6 5.2 4.8-5.6 
UTI^ caused by bacteria resistant to third-generation cephalosporins~ 1.8 0.4 4.5 4.1-4.9 
 
*See Table S2 for the sensitivity analysis calculating LTCF rates only for LTCFs in CE-pc. 
^ Urinary tract E. coli and Klebsiella reported to AmSurv.  
~ Third-generation cephalosporins include ceftazidime, cefpodoxime, cefotaxime, and ceftriaxone. 
 
 
 
 
 
 
 
 
 
Table 3. Prevalence of antibiotic resistance in all samples, in LTCF samples, in non-LTCF samples, in residential LTCF 
samples, and in nursing LTCF samples. 
Organism Antibiotic % resistance  % resistance  % resistance  % resistance  % resistance  
  overall LTCF samples Res LTCF 
samples 
Ns LTCF 
samples 
non-LTCF 
samples 
  n/N(%) n/N(%) n/N(%) n/N(%) n/N(%) 
E. coli 
  
  
  
Trimethoprim 61879/158764  9513/15914  5491/9438  4022/6476  52366/1428 
 (39.0%) (59.8%) (58.2%) (62.1%) 50 (36.7%) 
Nitrofurantoin 6322/158501  1059/15889  571/9425  488/6464  5263/14261 
 (4.0%) (6.7%) (6.1%) (7.6%) 2 (3.7%) 
Ciprofloxacin 16937/111220  3075/10564  1625/6100  1450/4464  13862/100656  
 (15.2%) (29.1%) (26.6%) (32.5%) (13.8%) 
Third-generation 
cephalosporins~ 
8581/134957  1412/13482  791/8084  621/5398  7169/121475  
  (6.4%) (10.5%) (9.8%) (11.5%) (5.9%) 
Klebsiella 
  
  
  
Trimethoprim 4759/17844  513/1257  282/707  231/550  4246/16587  
 (26.7%) (40.8%) (39.9%) (42.0%) (25.6%) 
Nitrofurantoin 4232/12159  377/916  213/517  164/399  3855/11243  
 (34.8%) (41.2%) (41.2%) (41.1%) (34.3%) 
Ciprofloxacin 1105/13738  95/918  48/510  47/408  1010/12820  
 (8.0%) (10.4%) (9.4%) (11.5%) (7.9%) 
Third-generation 
cephalosporins~ 
846/11593  60/754  29/430  31/324  786/10839  
  (7.3%) (8.0%) (6.7%) (9.6%) (7.3%) 
 
~ Third-generation cephalosporins include ceftazidime, cefpodoxime, cefotaxime, and ceftriaxone. 
 
 
Table 4. Unadjusted and adjusted odds ratio of antibiotic resistance in bacteria from LTCF samples compared to non-
LTCF samples. 
Bacterium Antibiotic uOR LTCF# Adjusted 95%CI 
uOR LTCF  
aOR^ LTCF Adjusted 95% CI 
aOR LTCF  
E. coli Trimethoprim 2.56 2.4 - 2.7 2.4 2.2 - 2.5 
Nitrofurantoin 1.86 1.6 - 2.1 1.7 1.5 - 2.0 
Ciprofloxacin 2.57 2.3 - 2.9 2.4 2.2 - 2.7 
Third-generation cephalosporins~ 1.86 1.6 - 2.1 1.9 1.6 - 2.2 
Klebsiella Trimethoprim 2.01 1.7 - 2.4 1.9 1.6 - 2.2 
Nitrofurantoin 1.34 1.1 - 1.6 1.3 1.1 - 1.6 
Ciprofloxacin 1.36 1.0 - 1.9 1.5 1.1 - 2.1 
Third-generation cephalosporins~ 1.1 0.8 - 1.6 1.2 0.9 - 1.8 
#uOR LTCF is the unadjusted odds ratio (univariable analysis) of antibiotic resistance in bacteria from 
LTCF samples compared to non-LTCF samples with 95% CIs adjusted for clustering at the postcode 
level 
^aOR LTCF is the adjusted OR, adjusted for age group, sex, year of study, and sender as categorical 
covariates of antibiotic resistance in bacteria from LTCF samples compared to non-LTCF samples 
with 95% CIs adjusted for clustering at the postcode level. Interactions were not included in the 
model as they did not improve model fit (see Table S1). 
~ Third-generation cephalosporins include ceftazidime, cefpodoxime, cefotaxime, and ceftriaxone. 
 
 
 
 
 
Figure legends 
Figure 1. Percentage of Klebsiella and E. coli samples resistant to trimethoprim, nitrofurantoin, third-generation 
cephalosporins, and ciprofloxacin. The black line represents LTCF samples and the grey line represents non-LTCF samples. 
Yearly point estimates are presented with 95% binomial CIs. Third-generation cephalosporins include ceftazidime, 
cefpodoxime, cefotaxime, and ceftriaxone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 
 
